These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21422817)

  • 1. In vitro and in vivo cleavage of HIV-1 RNA by new SOFA-HDV ribozymes and their potential to inhibit viral replication.
    Lainé S; Scarborough RJ; Lévesque D; Didierlaurent L; Soye KJ; Mougel M; Perreault JP; Gatignol A
    RNA Biol; 2011; 8(2):343-53. PubMed ID: 21422817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev.
    Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K
    Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mimicry of the hepatitis delta virus replication cycle mediated by synthetic circular oligodeoxynucleotides.
    Diegelman AM; Kool ET
    Chem Biol; 1999 Aug; 6(8):569-76. PubMed ID: 10421762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target-induced SOFA-HDV ribozyme.
    Lévesque MV; Perreault JP
    Methods Mol Biol; 2012; 848():369-84. PubMed ID: 22315081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of HDV ribozymes to trans-cleave HCV RNA.
    Yu YC; Mao Q; Gu CH; Li QF; Wang YM
    World J Gastroenterol; 2002 Aug; 8(4):694-8. PubMed ID: 12174380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
    Sun LQ; Wang L; Gerlach WL; Symonds G
    Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes.
    Zhou C; Bahner IC; Larson GP; Zaia JA; Rossi JJ; Kohn EB
    Gene; 1994 Nov; 149(1):33-9. PubMed ID: 7958986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model.
    Bai J; Banda N; Lee NS; Rossi J; Akkina R
    Mol Ther; 2002 Dec; 6(6):770-82. PubMed ID: 12498773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of the most potent specific on/off adaptor-hepatitis delta virus ribozymes for use in gene targeting.
    Lévesque MV; Rouleau SG; Perreault JP
    Nucleic Acid Ther; 2011 Aug; 21(4):241-52. PubMed ID: 21793786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic Parameters of trans Scission by Extended HDV-like Ribozymes and the Prospect for the Discovery of Genomic trans-Cleaving RNAs.
    Webb CT; Lupták A
    Biochemistry; 2018 Mar; 57(9):1440-1450. PubMed ID: 29388767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates.
    Chen CJ; Banerjea AC; Harmison GG; Haglund K; Schubert M
    Nucleic Acids Res; 1992 Sep; 20(17):4581-9. PubMed ID: 1408760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catalytic strategies of the hepatitis delta virus ribozymes.
    Shih IH; Been MD
    Annu Rev Biochem; 2002; 71():887-917. PubMed ID: 12045114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A circular trans-acting hepatitis delta virus ribozyme.
    Puttaraju M; Perrotta AT; Been MD
    Nucleic Acids Res; 1993 Sep; 21(18):4253-8. PubMed ID: 7692400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and evaluation of clinically relevant SOFA-HDV ribozymes targeting HIV RNA.
    Scarborough RJ; Lévesque MV; Perreault JP; Gatignol A
    Methods Mol Biol; 2014; 1103():31-43. PubMed ID: 24318884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating a new generation of ribozymes in order to target HCV.
    Lévesque MV; Lévesque D; Brière FP; Perreault JP
    PLoS One; 2010 Mar; 5(3):e9627. PubMed ID: 20224783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defective HIV-1 provirus encoding a multitarget-ribozyme inhibits accumulation of spliced and unspliced HIV-1 mRNAs, reduces infectivity of viral progeny, and protects the cells from pathogenesis.
    Paik SY; Banerjea A; Chen CJ; Ye Z; Harmison GG; Schubert M
    Hum Gene Ther; 1997 Jun; 8(9):1115-24. PubMed ID: 9189769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of five highly conserved target sites within the HIV-1 RNA for their susceptibility to hammerhead ribozyme-mediated cleavage in vitro and in vivo.
    Ramezani A; Joshi S
    Antisense Nucleic Acid Drug Dev; 1996; 6(3):229-35. PubMed ID: 8915508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent inhibition of HIV-1 gene expression and TAT-mediated apoptosis in human T cells by novel mono- and multitarget anti-TAT/Rev/Env ribozymes and a general purpose RNA-cleaving DNA-enzyme.
    Unwalla H; Chakraborti S; Sood V; Gupta N; Banerjea AC
    Antiviral Res; 2006 Nov; 72(2):134-44. PubMed ID: 16790281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of HIV-1 envelope protein synthesis by Tat and Rev in 293 cells.
    Natarajan V; Radjendirane V; Salzman NP
    Virology; 1993 Sep; 196(1):122-9. PubMed ID: 8356789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection in vitro of trans-acting genomic human hepatitis delta virus (HDV) ribozymes.
    Nishikawa F; Kawakami J; Chiba A; Shirai M; Kumar PK; Nishikawa S
    Eur J Biochem; 1996 May; 237(3):712-8. PubMed ID: 8647117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.